Pet Vivo Holdings, Inc. PETV
We take great care to ensure that the data presented and summarized in this overview for PetVivo Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PETV
View all-
Bard Associates Inc Chicago, IL419KShares$255,4640.17% of portfolio
-
Warberg Asset Management LLC Winnetka, IL111KShares$67,7710.84% of portfolio
-
Geode Capital Management, LLC Boston, MA65KShares$39,6210.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA59.9KShares$36,5110.0% of portfolio
-
State Street Corp Boston, MA46.2KShares$28,1990.0% of portfolio
-
Cultivar Capital, Inc. Denton, TX20.4KShares$12,4280.02% of portfolio
-
Regal Investment Advisors LLC Kentwood, MI19KShares$11,5900.0% of portfolio
-
Mariner, LLC Overland Park, KS18.3KShares$11,1320.0% of portfolio
-
High Tower Advisors, LLC Chicago, IL14.6KShares$8,9170.0% of portfolio
-
Asset Dedication, LLC14.6KShares$8,8870.0% of portfolio
Latest Institutional Activity in PETV
Top Purchases
Top Sells
About PETV
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
Insider Transactions at PETV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 15
2024
|
John Lai CEO and President |
BUY
Open market or private purchase
|
Direct |
150,000
+10.43%
|
$0
$0.6 P/Share
|
|
Aug 21
2023
|
James Rudolph Martin Director |
BUY
Open market or private purchase
|
Direct |
22,224
+1.32%
|
$44,448
$2.26 P/Share
|
|
Aug 19
2023
|
Joseph William Jasper Director |
BUY
Payment of exercise price or tax liability
|
Direct |
12,212
+26.0%
|
$12,212
$1.33 P/Share
|
|
Mar 15
2023
|
Robert J Costantino Director |
BUY
Open market or private purchase
|
Direct |
3,350
+10.82%
|
$10,050
$3.03 P/Share
|
|
Mar 13
2023
|
Joseph William Jasper Director |
BUY
Open market or private purchase
|
Indirect |
2,000
+50.0%
|
$6,000
$3.1 P/Share
|
|
Mar 01
2023
|
Joseph William Jasper Director |
BUY
Open market or private purchase
|
Direct |
500
+2.17%
|
$1,000
$2.94 P/Share
|
|
Feb 28
2023
|
Joseph William Jasper Director |
BUY
Open market or private purchase
|
Direct |
501
+2.22%
|
$1,503
$3.12 P/Share
|
|
Feb 27
2023
|
Joseph William Jasper Director |
BUY
Open market or private purchase
|
Direct |
1,399
+3.17%
|
$2,798
$2.96 P/Share
|
|
Feb 24
2023
|
Joseph William Jasper Director |
BUY
Open market or private purchase
|
Direct |
2,600
+6.09%
|
$5,200
$2.97 P/Share
|
|
Feb 24
2023
|
John Lai CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
60,600
+5.05%
|
-
|
|
Feb 21
2023
|
James Rudolph Martin Director |
BUY
Open market or private purchase
|
Direct |
3,300
+0.86%
|
$6,600
$2.99 P/Share
|
|
Feb 16
2023
|
James Rudolph Martin Director |
BUY
Open market or private purchase
|
Direct |
103
+0.09%
|
$206
$2.99 P/Share
|
|
Feb 15
2023
|
James Rudolph Martin Director |
BUY
Open market or private purchase
|
Direct |
8,400
+2.16%
|
$16,800
$2.71 P/Share
|
|
Feb 14
2023
|
James Rudolph Martin Director |
BUY
Open market or private purchase
|
Direct |
7,899
+1.71%
|
$15,798
$2.6 P/Share
|
|
Nov 22
2022
|
John Lai CEO and President |
BUY
Open market or private purchase
|
Direct |
1,000
+0.1%
|
$2,000
$2.5 P/Share
|
|
Nov 21
2022
|
Robert James Rudelius Director |
BUY
Open market or private purchase
|
Direct |
860
+0.41%
|
$1,720
$2.65 P/Share
|
|
Nov 21
2022
|
John Lai CEO and President |
BUY
Open market or private purchase
|
Direct |
1,000
+0.1%
|
$2,000
$2.55 P/Share
|
|
Nov 18
2022
|
Robert James Rudelius Director |
BUY
Open market or private purchase
|
Direct |
1,640
+0.39%
|
$3,280
$2.58 P/Share
|
|
Nov 18
2022
|
John Lai CEO and President |
BUY
Open market or private purchase
|
Direct |
1,110
+0.06%
|
$2,220
$2.59 P/Share
|
|
Nov 17
2022
|
John Lai CEO and President |
BUY
Open market or private purchase
|
Direct |
1,856
+0.1%
|
$3,712
$2.48 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 172K shares |
|---|---|
| Payment of exercise price or tax liability | 12.2K shares |